scholarly journals Targeted Palliative Radionuclide Therapy for Metastatic Bone Pain

2020 ◽  
Vol 9 (8) ◽  
pp. 2622 ◽  
Author(s):  
Reyhaneh Manafi-Farid ◽  
Fardad Masoumi ◽  
Ghasemali Divband ◽  
Bahare Saidi ◽  
Bahar Ataeinia ◽  
...  
Keyword(s):  
Radionuclide Therapy ◽  
Bone Pain ◽  
Response Rate ◽  
Pain Palliation ◽  
Simultaneous Treatment ◽  
Bone Pain Palliation ◽  
Wide Range ◽  
Metastatic Bone Pain ◽  
Multiple Bone Metastases

Bone metastasis develops in multiple malignancies with a wide range of incidence. The presence of multiple bone metastases, leading to a multitude of complications and poorer prognosis. The corresponding refractory bone pain is still a challenging issue managed through multidisciplinary approaches to enhance the quality of life. Radiopharmaceuticals are mainly used in the latest courses of the disease. Bone-pain palliation with easy-to-administer radionuclides offers advantages, including simultaneous treatment of multiple metastatic foci, the repeatability and also the combination with other therapies. Several β¯- and α-emitters as well as pharmaceuticals, from the very first [89Sr]strontium-dichloride to recently introduced [223Ra]radium-dichloride, are investigated to identify an optimum agent. In addition, the combination of bone-seeking radiopharmaceuticals with chemotherapy or radiotherapy has been employed to enhance the outcome. Radiopharmaceuticals demonstrate an acceptable response rate in pain relief. Nevertheless, survival benefits have been documented in only a limited number of studies. In this review, we provide an overview of bone-seeking radiopharmaceuticals used for bone-pain palliation, their effectiveness and toxicity, as well as the results of the combination with other therapies. Bone-pain palliation with radiopharmaceuticals has been employed for eight decades. However, there are still new aspects yet to be established.

Metastatic bone pain palliation with 89‐Sr and 186‐Re‐HEDP in breast cancer patients

2001 ◽  
Vol 66 (2) ◽  
pp. 101-109 ◽  
Author(s):  
Rosa Sciuto ◽  
Anna Festa ◽  
Rosella Pasqualoni ◽  
Alessandro Semprebene ◽  
Sandra Rea ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Bone Pain ◽  
Pain Palliation ◽  
Breast Cancer Patients ◽  
Bone Pain Palliation ◽  
Metastatic Bone Pain

scholarly journals Metastatic Bone Pain Palliation using177Lu-Ethylenediaminetetramethylene Phosphonic Acid

2015 ◽  
Vol 14 (2) ◽  
pp. 109 ◽  
Author(s):  
Mehrosadat Alavi ◽  
Shapour Omidvari ◽  
Alireza Mehdizadeh ◽  
AmirR Jalilian ◽  
Ali Bahrami-Samani
Keyword(s):  
Phosphonic Acid ◽  
Bone Pain ◽  
Pain Palliation ◽  
Bone Pain Palliation ◽  
Metastatic Bone Pain

scholarly journals Retrospective evaluation of bone pain palliation after samarium-153-EDTMP therapy

2004 ◽  
Vol 59 (6) ◽  
pp. 321-328 ◽  
Author(s):  
Marcelo Tatit Sapienza ◽  
Carla Rachel Ono ◽  
Maria Inês Cury Guimarães ◽  
Tomoco Watanabe ◽  
Paulo Aguirre Costa ◽  
...  
Keyword(s):  
Bone Pain ◽  
Absorbed Dose ◽  
Pain Palliation ◽  
Weak Correlation ◽  
Pain Scores ◽  
Bone Pain Palliation ◽  
Pearson Coefficient ◽  
Subjective Scale ◽  
Metastatic Bone Pain

PURPOSE: The aim of this study was to evaluate the degree of metastatic bone pain palliation and medullar toxicity associated with samarium-153-EDTMP treatment. METHODS: Seventy-three patients with metastatic bone pain having previously undergone therapy with samarium-153-EDTMP (1 mCi/kg) were retrospectively evaluated. Routine follow-up included pain evaluation and blood counts for 2 months after treatment. Pain was evaluated using a subjective scale (from 0 to 10) before and for 8 weeks after the treatment. Blood counts were obtained before treatment and once a week for 2 months during follow-up. Dosimetry, based upon the urinary excretion of the isotope, was estimated in 41 individuals, and the resulting radiation absorbed doses were correlated with hematological data. RESULTS: Reduction in pain scores of 75% to 100% was obtained in 36 patients (49%), with a decrease of 50% to 75%, 25% to 50%, and 0% to 25% in, respectively, 20 (27%), 10 (14%), and 7 (10%) patients. There was no significant relationship between the pain response and location of the primary tumor (breast or prostate cancer). Mild to moderate myelosuppression was noted in 75.3% of patients, usually with hematological recovery at 8 weeks. The mean bone marrow dose was 347 ± 65 cGy, and only a weak correlation was found between absorbed dose and myelosuppression (Pearson coefficient = .4). CONCLUSIONS: Samarium-153-EDTMP is a valuable method for metastatic bone pain palliation. A mild to moderate and transitory myelosuppression is the main toxicity observed after samarium therapy, showing a weak correlation with dosimetric measures.

Samarium-153 EDTMP for metastatic bone pain palliation: The impact of europium impurities

2015 ◽  
Vol 31 (1) ◽  
pp. 104-107 ◽  
Author(s):  
J.A. Kalef-Ezra ◽  
S.T. Valakis ◽  
S. Pallada
Keyword(s):  
Bone Pain ◽  
Pain Palliation ◽  
Bone Pain Palliation ◽  
Metastatic Bone Pain ◽  
The Impact

186Re-1,4,8,11-tetraaza cyclotetradecyl-1,4,8,11-tetramethylene phosphonic acid: a novel agent for possible use in metastatic bone-pain palliation

2001 ◽  
Vol 28 (6) ◽  
pp. 709-717 ◽  
Author(s):  
Kanchan Kothari ◽  
Grace Samuel ◽  
Sharmila Banerjee ◽  
P.R Unni ◽  
H.D Sarma ◽  
...  
Keyword(s):  
Phosphonic Acid ◽  
Bone Pain ◽  
Pain Palliation ◽  
Bone Pain Palliation ◽  
Metastatic Bone Pain ◽  
Novel Agent

An electrochemical approach for removal of radionuclidic contaminants of Eu from 153 Sm for effective use in metastatic bone pain palliation

2018 ◽  
Vol 58 ◽  
pp. 8-19 ◽  
Author(s):  
Rubel Chakravarty ◽  
Sudipta Chakraborty ◽  
Mohammed Sahiralam Khan ◽  
Ramu Ram ◽  
Haladhar Dev Sarma ◽  
...  
Keyword(s):  
Bone Pain ◽  
Pain Palliation ◽  
Bone Pain Palliation ◽  
Electrochemical Approach ◽  
Metastatic Bone Pain ◽  
Effective Use

Treatment of painful bone metastases in prostate and breast cancer patients with the therapeutic radiopharmaceutical rhenium-188-HEDP

2016 ◽  
Vol 55 (05) ◽  
pp. 188-195 ◽  
Author(s):  
Floor Overbeek ◽  
John de Klerk ◽  
Pieternel Pasker-de Jong ◽  
Alexandra van den Berk ◽  
Rob ter Heine ◽  
...  
Keyword(s):  
Bone Metastases ◽  
Clinical Benefit ◽  
Response Rate ◽  
Clinical Care ◽  
Pain Response ◽  
Pain Palliation ◽  
Breast Cancer Patients ◽  
Routine Clinical Care ◽  
Painful Bone Metastases

Summary Aim: Rhenium-188-HEDP (188Re-HEDP) is an effective radiopharmaceutical for the palliative treatment of osteoblastic bone metastases. However, only limited data on its routine use are available and its effect on quality of life (QoL) has not been studied. Therefore, we evaluated the clinical benefit of 188Re-HEDP in routine clinical care. Patients and methods: Prostate or breast cancer patients with painful bone metastases receiving 188Re-HEDP as a routine clinical procedure were eligible for evaluation. Clinical benefit was assessed in terms of efficacy and toxicity. Pain palliation and QoL were monitored using the visual analogue scale (VAS), corrected for opioid intake, and the EORTC QLQ-C30 Global health status/QoL-scale. Thrombocyte and leukocyte nadirs were used to assess haematological toxicity. Results: 45 and 47 patients were evaluable for pain palliation and QoL, respectively. After a single injection of 188Re-HEDP, the overall pain response rate was 69% and mean VAS-scores decreased relevantly and significantly (p < 0.05). Repeated treatment resulted in similar pain response. The overall QoL response rate was 68% and mean Global health status/QoL-scores increased relevantly and significantly. Haematological side effects were mild and transient. Conclusion: The clinically relevant response on pain and quality of life and the limited adverse events prove clinical benefit of treatment with 188Re-HEDP and support its use in routine clinical care. Its effectiveness appears comparable to that of external beam radiotherapy.

Sign in / Sign up

Export Citation Format

Share Document